Sickle Cell Disease Linked to Higher Risk of Retinal Vascular Occlusion
Patients with hemoglobin SS sickle cell disease type may experience a significantly elevated risk of retinal vascular occlusion.
Study Links DOACs to Reduction in RVO, Intraocular Bleeding Risk
A first-time comparison in US patients displays the protective association of DOACs over warfarin use on RVO and intraocular bleeding risk.
Teleretinal Screening Motivates Sickle Cell Patients to Seek Eye Care
A teleretinal screening program improved the awareness of sickle cell retinopathy and motivated patients to visit an eye care provider.
Age Influences Anti-VEGF Effectiveness in DME Treatment
Older patient age was linked to suboptimal anti-VEGF response for diabetic macular edema in DRCR clinical trials.
Macular Atrophy Progresses Similarly in Wet and Dry AMD Types
Geographic atrophy in eyes with dry AMD and macular atrophy in fellow eyes with neovascular AMD demonstrate similar growth rates.
HCPLive Five at ASRS 2024
Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key interviews from the American Society of Retina Specialists (ASRS) 42nd Annual Meeting.
Jordana Fein, MD: Pre-Dose IOP Outcomes After Aflibercept 8 mg for DME
Pre-dose IOP outcomes in eyes with DME receiving aflibercept 8 mg or 2 mg were comparable through Week 48 of the Phase 2/3 PHOTON trial.
Diana Do, MD: Impact of Baseline BCVA on Aflibercept 8 mg Outcomes in DME
A post hoc analysis of PHOTON showed the utility of aflibercept 8 mg in patients with DME, irrespective of baseline visual acuity.
Top Gene Therapy News at ASRS 2024
A recap of the 5 most popular topics related to gene therapy in ophthalmology coming from the 42nd American Society of Retina Specialists meeting.
Ophthalmologists, Patients Hesitate to Switch to Anti-VEGF Biosimilars
Hesitancy with anti-VEGF biosimilars was identified in a survey among both ophthalmologists and patients with nAMD in Canada.
Capability of ChatGPT Reduced in Complex Vitreoretinal Scenarios
Across 40 clinical scenarios, ChatGPT did not provide a comprehensive response in 50% of clinical questions with nearly 30% hallucinated sources.
Male Sex, Younger Age Linked to Sickle Cell Retinopathy Progression
Patient factors trended towards an association with a higher risk of proliferative sickle cell retinopathy but did not reach statistical significance.
Sozinibercept Combination Therapy Exhibits Durability for nAMD, DME
Intravitreal dosing of sozinibercept up to 2 mg in combination with ranibizumab or aflibercept was well tolerated and supported ≥Q8W dosing intervals.
Semaglutide May Reduce Rates of Diabetic Retinopathy Outcomes
A database analysis linked semaglutide use to notable reductions in the rates of diabetic macular edema and vitreous hemorrhage in diabetic retinopathy.
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X
Presented at ASRS 2024, late-breaking RHONE-X data shows more than 90% of patients experienced the absence of DME after four years of faricimab.
FDA Accepts sBLA for Susvimo in Treatment of DME, Diabetic Retinopathy
The FDA accepted Genentech’s supplemental BLA for Susvimo, based on the one-year results from the Phase III Pagoda and Pavilion studies.
Dilraj Grewal, MD: Development of MNV in Geographic Atrophy in GATHER Trials
Eyes with GA that developed MNV in the GATHER trials experienced a slower growth rate with avaincaptad pegol than with sham treatment.
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy
Patients treated with PDS with ranibizumab refilled every nine months maintained vision improvements and experienced consistent safety over two years.
Study Links Maternal Asthma to Blinding Eye Disease in Premature Infants
New research presented at ASRS 2024 links maternal asthma to a higher risk of advanced retinopathy of prematurity.
Once-Daily Gildeuretinol Acetate Could Halt Progression of Early Stargardt Disease
New data from the TEASE-3 trial presented at the ASRS meeting shows gildeuretinol acetate may blunt disease progression in early-stage Stargardt disease patients.
Carl C. Awh, MD: Two-Year Outcomes of the Port Delivery System for DME
Over 2 years, the Port Delivery System demonstrated continued efficacy with fixed refill-exchange procedures every 24 weeks in the Phase 3 Pagoda trial.
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort
Interim results from the PRISM population extension cohort found that 4D-150 was well tolerated and reduced the mean annualized anti-VEGF injection rate.
NEPTUNE: Oral Brepocitinib Effective in Non-infectious Uveitis at 24 Weeks
At 24 weeks, the oral therapy was well-tolerated and the safety profile remained in line with previous brepocitinib studies and the pharmacological class.
OCU400 Shows Benefit for Retinitis Pigmentosa in Phase 1/2 Data
One-year 1/2 data examines the safety and efficacy of OCU400 gene therapy for the treatment of retinitis pigmentosa.
RHONE-X: 90% of Patients Treated with Faricimab Free from DME at 4 Years
New data from RHONE-X at ASRS suggest over 90% of DME patients treated with faricimab (Vabysmo) were DME-free at 4 years, with nearly 80% on 3-4 month dosing intervals.
Nonsterile Gloves Offer Little Protection Against Post-Injection Endophthalmitis, Study Finds
An ASRS 2024 study found no significant difference in post-injection endophthalmitis rates between using nonsterile gloves and not using gloves for anti-VEGF injections.
RESTORE: MCO-010 Significantly Improves Visual Acuity in Retinitis Pigmentosa
Topline Phase 2b/3 results show high- and low-dose MCO-010 treatment improved BCVA compared to control through 100 weeks.
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD
A single Ixo-vec injection showed up to a 95% reduction in annualized anti-VEGF injections, according to first-time 26-week results from the Phase 2 LUNA study.
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry
Pegcetacoplan for 36 months led to fewer absolute scotomatous points on microperimetry than delayed treatment, suggesting its efficacy in preserving vision.
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD
RGX-314 produced by the NAVXpress platform process showed a similar clinical profile to the adherent cell culture process in this Phase 2 pharmacodynamic study.
